Before initiation of testosterone replacement therapy, an examination of the prostate and assessment of prostate symptoms should be performed, and both the hematocrit and lipid profile should be measured. Hematocrit and prostate-specific antigen (PSA) levels should be measured 3 to 6 months after treatment initiation and then annually. A disadvantage of the injections is the fluctuation in serum testosterone concentration that can cause fluctuating libido, energy level, and mood. If the testosterone levels are equivocal, consider checking a free or bioavailable testosterone level. There is some evidence that a glucose load can significantly decrease testosterone levels for a short time, so conducting this test in the fasting state may result in improved accuracy (13). Serum testosterone levels exhibit ultradian and circadian variation, providing physiologic sources of biologic variability.
Despite these limitations, we believe this study has important strengths, including a large sample size, representation of all U.S. geographic regions, access to detailed laboratory data, and inclusion of a broad age range. Third, information on the physician who prescribed the medication was not available in this data source, and we were unable to determine whether or not patients who were seen by an endocrinologist or urologist were prescribed testosterone by another provider. Moreover, our data would not have captured testosterone laboratory tests that were conducted at a Veterans Affairs clinic or a commercial testosterone clinic. We also reported that 39.3% of new testosterone users did not have a serum PSA test conducted in the 12 months before treatment, and 56.7% did not have this test conducted in the 12 months following treatment. It is unclear why such a large percentage of patients failed to receive the recommended testosterone assessment either before or after initiating treatment.
A hematocrit test is recommended prior to therapy initiation to establish a baseline for future monitoring. Other potential side effects of TRT include fluid retention, acne, sleep apnea, gynecomastia, and infertility (11). Further studies are needed to determine the exact role of testosterone and TRT in cardiovascular risk. Improvement in bone mineral density has been reported, but no studies exist that determine whether the risk of fractures in these patients decreases when receiving TRT (11, 12, 18). Obese patients should also be assessed for obstructive sleep apnea, which is also an important cause of low T (16). It is therefore important to recommend weight loss either prior to or concomitant with TRT in obese patients.
Fourth, information on race/ethnicity and socioeconomic status was not available for the study population. For example, prescription claims data do not capture information on pharmaceutical agents purchased outside the plan. Second, inherent in analyses of administrative claims databases is the possibility of inaccurate or incomplete data. It is important to note, however, that a substantial number of men may have taken treatment for only a brief period (27 These men were less likely to have received guideline--concordant care compared with those treated by other specialties, including primary care. Patients in the oldest age group (≥70 years of age) had lower odds of receiving a serum PSA test than younger men.
Let’s get into how you can recognize the signs of high T levels in people with penises and people with vulvas, how it’s diagnosed, and what to do about it. T typically occurs in much higher levels in people with penises, but it’s also present in the bodies of people with vulvas in much lower concentrations. A doctor can help determine the best course of treatment, which may include medications and lifestyle changes. It is known that testosterone stimulates bone marrow production of erythrocytes, which might result in an increased hematocrit in some men, and therefore this should be checked at the same time as the PSA level.2,3 Examination of the prostate should be performed routinely, although the exact frequency after initiation of testosterone replacement is still debatable.